Drug Profile
ASN 100
Alternative Names: ASN-1; ASN-1 and ASN-2; ASN-100; ASN-2; ASN-3Latest Information Update: 30 May 2019
Price :
$50
*
At a glance
- Originator Adimab; Arsanis
- Developer Arsanis
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Bacterial toxin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Staphylococcal infections
Most Recent Events
- 13 Apr 2019 Pharmacodynamics, efficacy and adverse events data from a phase II trial in Staphylococcal infections presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2019)
- 13 Mar 2019 X4 Pharmaceuticals merged with Arsanis to form X4 Pharmaceuticals
- 31 Dec 2018 ASN 100 is available for licensing as of 14 Mar 2019. https://www.sec.gov/Archives/edgar/data/1501697/000156459019007097/asns-10k_20181231.htm 3381611